The total number of somatic mutations per coding region of genome defines the mutational burden of the cancer type, and has been correlated with response to anti‐Programmed cell death protein 1 therapy, and is therefore a proxy for the number of neoantigens presented by tumour cells [10, 11]. The gene discussed is PDCD1; the disease is cancer.